Smith & Wesson went back to the drawing board with its Bodyguard .380, and in 2024, the company rolled out the Bodyguard 2.0, ...
Findings further demonstrate the effectiveness of Roche's approved medicines in advancing treatment standards for people with blood disorders Data from innovative pipeline signals progress ...
2-11 NXT007: Positive phase I/II results, including new data from a global study in people with haemophilia A with and without factor VIII inhibitors, suggest the potential of Roche’s next-generation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback